Immunicom
  • About us
  • Leadership
  • History
  • News
  • About us
  • Leadership
  • History
  • News

Immunicom Inc.

HEADQUARTERS

San Diego, CA

6048 Cornerstone Ct W
Suite D
San Diego, CA 92121

RESOURCES

Terms of Use
Privacy policy

GET IN TOUCH

Contact us

Immunicom’s Immunopheresis TM therapy, including the LW-02 blood-filtering immunotherapy device, has not been approved by the US Food and Drug Administration and is an investigational therapy in all of Immunicom’s ongoing clinical research studies. Immunicom’s LW-02 blood-filtering immunotherapy device has been granted European CE Mark Certification for use in adults with advanced, refractory, triple-negative breast cancer in Europe.

© 2021 — Immunicom, Inc. All Rights Reserved.

We use cookies and similar technologies to enable services and functionality on our site and to understand your interaction with our service. By clicking on accept, you agree to our use of such technologies for marketing and analytics.

Your choices regarding cookies on this site

Please choose whether this site may use Functional, Tracking and Performance cookies, as described below from the Privacy Policy: